Compare Invesco Galaxy Bitcoin ETF (BTCO) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco Galaxy Bitcoin ETF vs Crispr Therapeutics AG — how do they compare? Invesco Galaxy Bitcoin ETF trades at $64.35, while Crispr Therapeutics AG trades at $50.54 (market cap $4.97B). The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, Invesco Galaxy Bitcoin ETF nearer its low. Which is the better fit depends on your goals.
| BTCO | CRSP | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $125.14 | $76.78 |
52-Week Low | $58.40 | $44.34 |
Market Cap | — | $4.97B |
Enterprise Value | — | $3.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BTCO trades at $61.86, down 2.67% today amid mixed technical signals with a bullish overall trend but bearish moving averages. The stock faces resistance near $64-65 while finding support around $62-63. Financial ratios remain unavailable in current data, requiring deeper fundamental analysis.
The stock shows technical resilience despite recent selling pressure, with key support levels holding. Investment appeal depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and competitive pressures in its sector.
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
